28 January 2022 in Journal of Thrombosis and Haemostasis
Patients with severe hemophilia A (HA) have an increased risk of spontaneous and trauma-related bleeding due to a congenital absence of factor VIII (FVIII). Most severe HA patients use prophylactic FVIII concentrate which effect can be monitored with FVIII activity level measurement. However, FVIII activity level is less valuable in predicting the potential clinical bleeding risk. Some patients still experience breakthrough bleeds despite adequate FVIII trough levels, while others do not bleed with trough levels below threshold. This difference may be caused by inter-individual differences in pro- and anticoagulant factors, the so-called hemostatic balance. Thrombin generation assays (TGAs) measure the hemostatic balance as a whole. Thereby, the TGA may be a better tool in the guidance and monitoring of treatment in HA patients. In addition, TGAs offer the opportunity to determine the response to bypassing agents (BPAs) and treatment with non-factor replacement therapy, where FVIII activity assays are not suitable for monitoring. This review summarizes the current knowledge about monitoring different HA treatment modalities by TGA, as single treatment option and when used in a concomitant fashion.
26 September 2020 in Journal of Thrombosis and Haemostasis
BGBritta A.P. Laros‐Van Gorkom
Britta A.P. Laros‐Van Gorkom
+2
Background Clinical severity of hemophilia A (HA) varies possibly due to interplay of many factors in the hemostatic pathway. Pharmacokinetic monitoring of FVIII replacement therapy in HA patients consists of measuring FVIII activity levels and subsequent dose adjustment. The Nijmegen Hemostasis Assay (NHA) measures thrombin generation (TG) and plasmin generation (PG). Objective Determine differences in TG and PG between HA patients before and during a pharmacokinetic study and identify best parameters to develop a pharmacodynamic model. Methods Twenty‐five HA patients (baseline FVIII<1‐9 IU/dL) underwent a pharmacokinetic study with a single dose of 25‐50 IU/kg standard half‐life FVIII concentrate. At baseline and after administration of FVIII TG and PG parameters were measured with the NHA. Results FVIII activity level increased from median 1.0 IU/dL (interquartile range <1.0‐6.0) to 71 IU/dL (62‐82) 15 minutes after administration and decreased to 15 IU/dL (10‐26) at 24 hours. TG was enhanced simultaneously, with thrombin peak height (TPH) increasing from 22nM (15‐35) to 222nM (159‐255), and thrombin potential (TP) from 404nM/min (undetectable‐876) to 1834nM/min (1546‐2353). Twenty‐four hours after infusion, TG parameters remained high [TPH 73nM (58.5‐126.3); TP 1394nM/min (1066‐1677)] compared to FVIII activity level. PG showed hyperfibrinolysis in severe HA patients compared to mild patients and controls, which normalized after FVIII supplementation. Conclusion HA patients showed clear differences in baseline TG and PG despite having comparable FVIII activity levels. These results reveal a discrepancy between FVIII activity level and TG, in which the latter may be a better parameter to monitor individualized treatment in HA patients.
1 January 2015 in Transplant Immunology
15 March 2022 in Research and Practice in Thrombosis and Haemostasis
BGBritta A.P. Laros‐Van Gorkom
Britta A.P. Laros‐Van Gorkom
+1
Analysis of fibrinolytic disorders is challenging and may potentially lead to underdiagnosis of patients with an increased bleeding tendency. To compare clinical characteristics, laboratory measurements, and treatment modalities in a monocenter cohort of patients in whom fibrinolytic studies were performed. Retrospective study of patients in whom fibrinolytic studies were performed between January 2016 and February 2020 in the Hemophilia Treatment Center, Nijmegen‐Eindhoven‐Maastricht, the Netherlands. Plasminogen activator inhibitor type 1 (PAI‐1) antigen and activity level, α2‐antiplasmin activity, tissue plasminogen activator, and euglobulin clot lysis time (ECLT) before and after venous compression were determined in all patients. Data of bleeding assessment tool (BAT) score, clinical characteristics, results of primary and secondary hemostasis assays, and general treatment plans were collected. In total, 160 patients were included: 97 (61%) without and 63 (39%) with a laboratory‐based fibrinolytic disorder. Mean BAT score did not differ between the groups (9.3 vs 9.8, respectively). The presumptive fibrinolytic disorders were distributed as follows: 34 patients had an increased ECLT ratio or low baseline ECLT, 25 patients had low PAI‐1 antigen and activity level, and four patients had both. The majority of these patients were treated with tranexamic acid monotherapy (60%) with only 40% additional treatment options, whereas 80% of patients without a presumptive fibrinolytic disorder had multiple treatment modalities. Analysis of fibrinolytic disorders in selected patients has a high diagnostic yield. General incorporation of fibrinolytic analysis in the diagnostic workup of patients with bleeding of unknown cause can improve diagnosis and management of their bleeding episodes.
28 June 2020 in Haemophilia
NBNicole M. A. Blijlevens
9 September 2020 in Journal of Travel Medicine
A persisting leishmania parasite